Dosage of Fenocard H in details
General Considerations
Fenocard H Capsules should be given with meals thereby optimizing the absorption of the medication.
Patients should be advised to swallow Fenocard H Capsules whole. Do not open, crush, dissolve or chew capsules.
Patients should be placed on an appropriate lipid-lowering diet before receiving Fenocard H Capsules, and should continue this diet during treatment with Fenocard H Capsules.
The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.
Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of Fenocard H. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 150 mg per day.
Consideration should be given to reducing the dosage of Fenocard H if lipid levels fall significantly below the targeted range.
Primary Hypercholesterolemia or Mixed Dyslipidemia
The dose of Fenocard H Capsules is 150 mg once daily.
Severe Hypertriglyceridemia
The initial dose is 50 to 150 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determination at 4 to 8 week intervals.
The maximum dose of Fenocard H Capsules is 150 mg once daily.
Impaired Renal Function
In patients with mild-to-moderate renal impairment, treatment with Fenocard H Capsules should be initiated at a dose of 50 mg per day, and increased only after evaluation of the effects on renal function and lipid levels at this dose. The use of Fenocard H should be avoided in patients with severe renal impairment.
Geriatric Patients
Dose selection for the elderly should be made on the basis of renal function.
What other drugs will affect Fenocard H?
Tell your doctor about all medicines you use, and those you start or stop using during your treatment with Fenocard H, especially:
- a blood thinner such as warfarin, Coumadin;
- medicines to treat a bowel disorder;
- medication to prevent organ transplant rejection;
- antiviral medications;
- chemotherapy;
- pain or arthritis medicines (including aspirin, Tylenol, Advil, and Aleve); or
- any injected antibiotics.
This list is not complete. Other drugs may interact with Fenocard H, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Fenocard H interactions
Anticoagulants: Fenocard H enhances oral anticoagulant effect and may increase risk of bleeding. Therefore, this combination is not recommended.
Potentiation of coumarin-type anticoagulant effects has been observed with prolongation of the PT/INR.
Caution should be exercised when coumarin anticoagulants are given in conjunction with Fenocard H. The dosage of the anticoagulants should be reduced to maintain the PT/INR at the desired level to prevent bleeding complications. Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized.
Hydroxy methylglutaryl coenzyme A (HMG-CoA) Reductase Inhibitors (Statins): The combined use of Fenocard H and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.
The risk of serious muscle toxicity is increased if Fenocard H is used concomitantly with HMG-CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution and patients monitored closely for signs of muscle toxicity.
Bile Acid Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take Fenocard H at least 1 hr before or 4-6 hrs after a bile acid binding resin to avoid impeding its absorption.
Immunosuppressants: Immunosuppressants eg, cyclosporine and tacrolimus can produce nephrotoxicity with decreases in CrCl and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including Fenocard H, there is a risk that an interaction will lead to deterioration. The benefits and risks of using Fenocard H with immunosuppressants and other potentially nephrotoxic agents should be carefully considered and the lowest effective dose employed and renal function monitored.
Some severe cases of reversible renal function impairment have been reported during concomitant administration of Fenocard H and cyclosporine. The renal function of these patients must therefore be closely monitored and the treatment with Fenocard H stopped in the case of severe alteration of laboratory parameters.
Cytochrome P450 (CYP450) Enzymes: In vitro studies using human liver microsomes indicate that Fenocard H and fenofibric acid are not inhibitors of CYP450 isoforms CYP3A4, CYP2D6, CYP2E1 or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6 and mild to moderate inhibitors of CYP2C9 at therapeutic concentrations. Patients co-administered Fenocard H and CYP2C19, CYP2A6 and especially CYP2C9 metabolised drugs with a narrow therapeutic index should be carefully monitored and if necessary, dose adjustment of these drugs is recommended.
References
- DailyMed. "FENOFIBRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "U202363UOS: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Hypolipidemic Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Fenocard H are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Fenocard H. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yet1 consumer reported doses
What doses of Fenocard H drug you have used?The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Fenocard H drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
| Users | % | ||
|---|---|---|---|
| 11-50mg | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
